Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications

Rhea-AI Summary

Arima Genomics, Inc. has successfully closed a $7 million Series B Preferred Stock financing round, with participation from both new and existing investors, including Genetron Health and Agilent Technologies. The funds aim to accelerate innovation and expand the company’s capabilities in 3D genomics, which provides crucial insights into the structure of genomes, enhancing research and therapeutic development. Arima's technologies are increasingly recognized in precision oncology, with over 600 global customers and more than 200 peer-reviewed studies leveraging its products.

Positive

• Closed $7 million Series B Preferred Stock financing round.
• Funds will accelerate innovation and expand product portfolio.
• 3D genomics technology increasingly recognized in precision oncology applications.
• Over 600 global customers utilizing Arima's technologies.
• More than 200 peer-reviewed studies published using Arima's technology.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Arima Genomics, Inc., the leader in 3D genomics, today announced the close of its $7 million Series B Preferred Stock financing round. New investors Genetron Health (NASDAQ: GTH), Tech Coast Angels, Ladder Ventures, and Hiaqua Investments were joined by existing investors Agilent Technologies (NYSE: A), Co-win Ventures, Vectr Ventures, and Berkeley Catalyst Fund in partnering with the company to support its long-term growth and commercial expansion.

Arima Genomics’ technologies provide three-dimensional information about the genome. While most DNA sequencing methods provide linearized DNA data, those approaches do not capture critical DNA structural information. By connecting DNA sequence and structural data, Arima Genomics’ technologies can reveal new biological insights that are indispensable in a diverse set of applications, including helping researchers understand disease mechanisms needed to develop and optimize therapeutic approaches such as cell- and gene-based therapies.

“The increased adoption of 3D genomics indicates the value the life science community sees in understanding the physical organization of genes and how that organization works to drive function and disease,” said Darlene Solomon, Ph.D., Senior Vice President and Chief Technology Officer at Agilent Technologies. “Arima Genomics’ solutions help us to better understand this important structural layer of biology and the genetic underpinnings of diseases. This, in turn, helps researchers in the identification of important biomarkers.”

“We see great promise in Arima Genomics’ 3D genomic technologies, especially in emerging precision oncology applications,” said Hai Yan, M.D., Ph.D., Chief Scientific Officer at Genetron Health. “Arima Genomics' relationship with its more than 600 global customers is a testament to both its humble, science-led culture and the applicability of its product portfolio in driving discovery in critical clinical research programs.”

The funds will support an acceleration of innovation to expand the company’s product portfolio and bioinformatics capabilities to serve a broader spectrum of scientific and translational medicine applications. The funds will also be used to scale the organization to enhance operational and commercial capacity worldwide.

“The body of evidence surrounding the importance of genome structure in health and disease continues to grow – after all, unlike sequence, the structure is highly dynamic both spatially and temporally. Customers have leveraged our technology and published more than 200 peer-reviewed studies advancing the understanding of cancer, neurobiology, immunology, and other complex diseases,” said Siddarth Selvaraj, Chief Executive Officer and Co-founder of Arima Genomics. “As the importance of genomic structure as a driver of disease becomes better understood, we are well-positioned to support emerging research, drug discovery, and translational applications.”

About Arima Genomics

Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving and presenting the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005371/en/

For media

Gwen Gordon

858.245.5684

gwen@gwengordonpr.com

For general inquiries

Pamela Bentley Mills, PhD

415.802.3421

pamela@arimagenomics.com

Source: Arima Genomics, Inc.

FAQ

What is the significance of Arima Genomics' $7 million funding round on GTH,A?

The $7 million Series B funding round enhances Arima Genomics’ capacity for innovation in 3D genomics, positively impacting its growth and the broader life sciences sector.

How will the Series B funding help Arima Genomics?

The funds will support the expansion of Arima's product portfolio and bioinformatics capabilities, enhancing operational and commercial capacity worldwide.

Why is 3D genomics important for GTH,A investors?

3D genomics is vital as it provides insights into genomic structure, leading to advancements in precision oncology, which can drive growth and innovation for companies like Genetron Health.

What role do existing investors play in Arima Genomics’ financing round?

Existing investors, including Agilent Technologies, provide credibility and support for Arima's long-term growth through their participation in the $7 million financing round.

What are the applications of Arima Genomics' technology?

Arima Genomics' 3D genomics technology aids in understanding disease mechanisms and supports therapeutic approaches like cell- and gene-based therapies.